Ethoxylation capacity
66,000 MT
+15,000 MT YoY
New capacity commissioned in Q4 FY26; utilization near 90-100%.
ROSSARIBIOTECH
Information Technology
30 Apr 2026
Rossari Biotech Ltd — Q4 FY26
Rossari Biotech delivered a strong Q4 FY26 with revenue of ₹684.9 crore (+18% YoY) and EBITDA of ₹77.3 crore (+11% YoY), marking the highest-ever quarterly revenue and EBITDA.
✓ Verified against BSE filing
2-Min Summary
Rossari Biotech delivered a strong Q4 FY26 with revenue of ₹684.9 crore (+18% YoY) and EBITDA of ₹77.3 crore (+11% YoY), marking the highest-ever quarterly revenue and EBITDA. Growth was broad-based across all three segments (HPCC +20%, Textiles +10%, AHN +11%), driven by volume and customer engagement. EBITDA margin contracted 70 bps YoY to 11.3% due to raw material cost spikes (25-30% for some inputs) and a less favorable sales mix. Management guided for at least 15% revenue growth in FY27 and EBITDA margins of 12-13%, supported by new ethoxylation capacity, pharma/agro/oil & gas expansion, and cost optimization. Risks include geopolitical uncertainty in the Middle East and potential demand softness from El Niño.
Key Numbers
Exports growth (FY26)
11%
+11% YoY
Exports grew 11% in FY26, driven by Latin America, Europe, SE Asia, Africa.
Core B2B EBITDA margin
14%
N/A
Excluding institutional/B2C, core B2B delivered 14% EBITDA margin for FY26.
Top 10 customer concentration
12-13%
N/A
Revenue from top 10 customers is 12-13%; no single customer >2%.
Management Guidance
FY27 revenue growth of at least 15%
Management expects minimum 15% revenue growth in FY27, similar to FY26, with potential upside if global conditions improve.
revenueFY27 EBITDA margin of 12-13%
EBITDA margin expected to remain at current levels of 12-13% for FY27, with improvement from pharma and cost initiatives in H2.
marginsCapex of ₹50-75 crore in FY27
Capital expenditure for FY27 planned at ₹50-75 crore, focused on Saudi facility and aroma chemicals.
capexDebt-free target in 18 months
Management aims to significantly reduce debt and become debt-free within 18 months through cash flows and non-core asset sales.
otherKey Risks
Geopolitical uncertainty in Middle East
Ongoing conflict in the Middle East could disrupt supply chains, logistics, and demand, impacting near-term performance.
high · management_commentaryRaw material price volatility
March saw raw material price increases of 25-30%, which impacted gross margins; pass-through is ongoing but may face resistance in textiles.
medium · management_commentaryEl Niño impact on agro season
El Niño could affect the agro season and demand for agrochemicals, though management says it's too early to comment.
medium · analyst_questionExecution risk in Saudi expansion
The Saudi initiative is a key strategic step but faces uncertainties from geopolitical developments and may take time to ramp up.
medium · management_commentaryNotable Quotes
We concluded the year 26 on a very strong note with Q4 marking our highest ever quarterly revenue and AIDA performance for the full year.
Our focus remains on strengthening customer relationships, expanding the product market, improving market penetration, and building scale in relevant chemistries and applications.
The target is to actually get debt free by in the next 18 months but I think that the time is there but currently the plan is to keep bringing down our debts over the next 18 months.